The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; G1 Therapeutics; Genentech; ITeos Therapeutics; Janssen; Novartis; Sanofi; Surface Oncology
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)
 
Anna K. Nowak
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Douglas Pharmaceuticals; Epizyme; Merck Sharp & Dohme; Trizell
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Research Funding - AstraZeneca (Inst); Douglas Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Peey-Sei Kok
Honoraria - AstraZeneca/MedImmune; Pfizer
Consulting or Advisory Role - MSD
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Pfizer
Other Relationship - AstraZeneca (Inst); Roche (Inst)
 
Chris Brown
No Relationships to Disclose
 
Zhuoxin Sun
No Relationships to Disclose
 
Valsamo Anagnostou
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Kenneth John O'Byrne
Stock and Other Ownership Interests - Carpe Vitae Pharmaceuticals; DGC diagnostics; RepLuca Pharmaceuticals
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Takeda; TriStar Technology Group; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - I am named on 4 active patents, 2 published and 2 provisional (Inst)
 
Sonia Yip
No Relationships to Disclose
 
Alistair Cook
Research Funding - AstraZeneca Canada (Inst)
 
Willem Joost Lesterhuis
Consulting or Advisory Role - Douglas Pharmaceuticals
Research Funding - Axelia Oncology (Inst); Douglas Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - PCT/AU2021/050764
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Aventis; Takeda
Research Funding - Amgen (Inst)
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Julie R. Brahmer
Honoraria - Janssen
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Lilly; Merck; Regeneron; Sanofi; Turning Point Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); RAPT Therapeutics (Inst); Revolution (Inst); Spectrum Pharmaceuticals (Inst)
Other Relationship - Bristol-Myers Squibb
 
Hedy L. Kindler
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Deciphera; Inhibrx; Novocure; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Deciphera (Inst); Fibrogen (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Polaris (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); Verastem (Inst); Vivace Therapeutics (Inst)
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Lilly; Novartis; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Millennium; Polaris; Seagen; Seagen; Takeda
Patents, Royalties, Other Intellectual Property - UptoDate
 
Marjorie Glass Zauderer
Honoraria - Medical Learning Institute; OncLive Clinical Congress Consultants; Research to Practice
Consulting or Advisory Role - Aldeyra Therapeutics; GlaxoSmithKline; Novocure; Takeda
Research Funding - Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Polaris (Inst); Sellas Life Sciences (Inst)
(OPTIONAL) Uncompensated Relationships - Mesothelioma Applied Research Foundation
 
Suresh S. Ramalingam
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; GlaxoSmithKline; Lilly/ImClone; Merck; Mirati Therapeutics; Takeda
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - American Cancer Society
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer